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SUMMARY
Objective: The objective of this study was to evaluate the presence of vitamin B12 de-
ficiency and the factors associated with serum vitamin B12 levels in a sample of met-
formin-treated Brazilian diabetic patients. Method: Cross-sectional study. Results: 144 
patients were included. Serum vitamin B12 levels were low (< 125 pmol/L) in 10 patients 
(6.9%) and possibly low (125 - 250 pmol/L) in 53 patients (36.8%). Serum vitamin B12 
levels were negatively associated with age (B = -3.17; β= -0.171; p = 0.037) and duration 
of metformin use (B= -33.36; β= -0.161; p = 0.048), and positively associated with the 
estimated intake of vitamin B12 (B= 67.96; β= 0.249; p = 0.002). Conclusion: The pres-
ent findings suggest a high prevalence of vitamin B12 deficiency in metformin-treated 
diabetic patients. Older patients, patients in long term treatment with metformin and 
low vitamin B12 intake are probably more prone to this deficiency.
Keywords: Diabetes mellitus; vitamin B 12; metformin.
RESUMO
Vitamina B12 em pacientes diabéticos usando metformina: um corte 
transversal no Brasil 
Objetivo: O objetivo deste estudo foi avaliar a prevalência de deficiência de vitamina B12 
em pacientes diabéticos brasileiros tratados com metformina e os fatores associados aos 
níveis séricos de vitamina B12. Método: Corte transversal. Resultados: 144 pacientes 
foram incluídos. Os níveis séricos de vitamina B12 foram baixos (< 125 pmol/L) em 10 
pacientes (6,9%) e possivelmente baixos (125 - 250pmol/L) em 53 pacientes (36,8%). 
Os níveis séricos de vitamina B12 foram associados negativamente à idade (B = -3,17; 
β = -0,171; p = 0,037) e à duração do uso de metformina (B = -33,36; β= -0,161; 
p = 0,048) e positivamente com a ingestão estimada de vitamina B12 (B = 67,96; 
β = 0,249; p = 0,002). Conclusão: Estes resultados sugerem alta prevalência de deficiên-
cia de vitamina B12 em pacientes diabéticos tratados com metformina. Pacientes mais 
velhos, em uso de metformina há muito tempo e com ingestão baixa de vitamina B12 
estão provavelmente mais predispostos a essa deficiência.
Unitermos: Diabetes mellitus; vitamina B 12; metformina.
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INTRODUCTION
Vitamin B12 deficiency can lead to hematological abnor-
malities, cognitive disorders, and neuropathy1. This vita-
min is obtained from animal origin food, so its deficiency 
may be related to eating habits, changes in the absorption 
or metabolic mechanisms.
Metformin is the first choice of treatment for type 2 
diabetes mellitus (DM2), decreasing insulin resistance, and 
cardiovascular and mortality risks. It is usually well tole-
rated, although it may cause gastrointestinal side-effects2.
The association of metformin with vitamin B12 defi-
ciency has been studied for some time, yet, the mechanism 
leading to this deficiency is not fully understood3,4. Recen-
tly, vitamin B12 deficiency has been associated with neuro-
pathy in metformin-treated diabetic patients5.
A literature review was made in the PubMed and 
LILACS databases combining the keywords: vitamin B12 
and metformin and no studies with Brazilian patients were 
identified until August, 2010. Given the importance of vi-
tamin B12 deficiency, this study aimed to estimate its pre-
valence and to evaluate factors associated with serum vita-
min B12 levels in metformin-treated DM2 patients, in the 
outpatient setting of a tertiary hospital in Southern Brazil. 
METHODS
All DM2 patients treated with metformin for more than 
one year in the ambulatory of Internal Medicine at the 
Hospital de Clinicas of Porto Alegre were invited to par-
ticipate, until completion of the sample. Patients with 
partial or total gastrectomy, Crohn’s disease, disorders of 
the terminal ileum and using supplemental vitamin B12 
were excluded. Factors evaluated in the study were age, 
gender, weight, metformin dosage, duration of metformin 
use, dietary intake of vitamin B12, red cell mean corpus-
cular volume (MCV), glycosylated hemoglobin and use of 
other medications or supplements.
Sample size was set to 147 patients estimating a 25% 
prevalence of vitamin B12 deficiency, with an accuracy of 
7%, and p < 0.05.
Intake of vitamin B12 was estimated by the 24-hour 
food recall method. The book Álbum fotográfico de porções 
alimentares. (Photographic Record for Dietary Inquiries): 
appliances and parts was used to illustrate the food por-
tions6. A table was used to convert approximate cooking 
measurements into grams 7. Based on this information, in-
take of vitamin B12 was estimated using a chart containing 
the amount of vitamin B12 in food in Brazil8. Vitamin B12 
intake was considered adequate or not according to the 
Dietary Reference Intake (DRI) for vitamin B12, as propo-
sed by the Institute of Medicine of the USA9. 
This study was approved by the Ethics Committee on 
Research of the Hospital de Clinicas de Porto Alegre and 
all patients signed an informed consent before entering 
the study. One blood sample from each patient was ob-
tained and serum samples were stored at - 70ºC. Vitamin 
B12 levels were determined in a single batch by electro-
chemiluminescence - Modular E170 Roche. Vitamin B12 
deficiency was defined by a serum level < 125 pmol/L and 
was considered possible when the serum level of vitamin 
B12 ranged from 125 pmol/L to 250 pmol/L10. 
Data analysis was performed with the Statistical Packa-
ge for the Social Sciences (SPSS) version 16.0. Association 
of serum vitamin B12 levels with the factors studied was 
evaluated by Spearman’s correlation test, Student’s t test 
or the Mann-Whitney test. All factors associated with the 
serum vitamin B12 levels with p ≤ 0.2 were included in a 
linear regression model to determine the factors indepen-
dently associated, as suggested by Altman11. The variables 
without normal distribution were transformed into their 
natural logarithms. Values of p < 0.05 were considered sta-
tistically significant. 
RESULTS
In the period from July 3 to August 13, 2009, 158 eligible 
patients were identified and all agreed to participate. Two 
patients were excluded for reporting irregular use of me-
tformin. Twelve patients were excluded for not undergoing 
blood collection. The analysis was done based on data ob-
tained from 144 patients. Characteristics of these patients 
are shown in Table 1. 
Serum vitamin B12 levels were low (< 125 pmol/l) in 
10 patients (6.9%) and possibly low (125 pmol/L to 250 
pmol/L) in 53 patients (36.8%) and were associated with 
age, estimated vitamin B12 intake and body weight, as 
shown in Figure 1. The association of metformin dose 
and duration of metformin use with serum vitamin B12 
levels was, respectively, r = -0.114, p = 0.173 and r = -0.128, 
p = 0.129. Sixty eight patients (47%) had adequate daily 
intake of vitamin B12 (≥ 2.4 μg). 
Table 1 – Characteristics of metformin-treated diabetic 
patients (n = 144)
Age (years) 63.7 ± 11.30
Women n (%) 91 (63.2)
Weight (kg) 80.3 ± 15.4
Height (m) 1.62 ± 0.09
BMI (kg/m²) 30.62 ± 5.18
Time using metformin (years) 4 (2/8.1)
Dose of metformin (mg) 2550 (1700/2550)
Use of omeprazole n(%) 57 (39.6)
Use of calcium carbonate n(%) 17 (11.8)
Hb A1c (%) 7.70 (6.88/9.73)
Red cell MCV (fL) 88.0 ± 4.6
Daily intake of B12 (μg) 2.25 (1.36/3.38)
Serum vitamin B12 (pmol/L) 311.0 ± 155.5
Data are expressed as mean ± standard deviation, median (25/75 
percentile) or n (%).
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There was no association of serum B12 levels with 
gender [men (n = 54): 311.6 ± 146.3 pmol/L and women 
(n = 90): 310.6 ± 161.6 pmol/L, p = 0.97], use of omepra-
zole [yes (n = 58): 301.0 ± 148.4 pmol/L and no (n=86): 
317.8 ± 160.6 pmol/L, p = 0.52], use of calcium [yes (n = 
17): 298.7 ± 204.4 pmol/L and no (n = 127): 312.6 ± 148.8 
pmol/L, p = 0.79] and red cell MCV (r = 0.035, p = 0.68) 
and glycosylated hemoglobin (r = 0.092, p = 0.28). 
The adjusted model included age, estimated daily intake 
of vitamin B12, body weight, dose of metformin and dura-
tion of metformin use, excluding in two stages the less signi-
ficant factors. Serum vitamin B12 levels were independently 
and negatively associated with age (B = -3.17; β = -0.171; 
p = 0.037) and duration of metformin use (B = -33.36; 
β= -0.161; p = 0.048), and positively associated with the es-
timated intake of vitamin B12 (B = 67.96; β = 0.249; p = 
0.002), as shown in Table 2.
DISCUSSION
In the present study serum vitamin B12 levels were low and 
possibly low in, respectively, 6.9% and 36.8% of the 144 di-
abetic patients treated with metformin for more than one 
year. The prevalence of vitamin B12 deficiency varies ac-
cording to the cutoff for serum vitamin B12 level used10,12. 
Ideally, the serum methylmalonic acid would be measured 
in patients with possibly low serum vitamin B12 levels1,13. 
Our results are quite similar to other recent cross 
sectional studies, that included 195 metformin-treated 
DM2 patients4: 79 (40.5%) had serum vitamin B12 levels 
between 73.8  and 258.3 pmol/L. Forty-three of these pa-
tients had elevation of either methylmalonic acid or ho-
mocysteine levels. 
Although most studies associate vitamin B12 defi-
ciency to prolonged use of metformin, a randomized 
study involving 400 patients with DM2 showed that with-
in only 16 weeks of   metformin use, patients had their 
mean serum folate and vitamin B12 levels  reduced in 7% 
and 14%, respectively, and a 4% increase in mean serum 
homocysteine levels14. 
Since the only source of this vitamin is food, diet has 
great importance in the prevention of its deficiency, never-
theless, the lack of a strong correlation between estimated 
daily intake of vit-amin B12 and serum vitamin B12 levels 
is possibly due to  this micronutrient store in the liver13. The 
method used in our study to estimate vitamin B12 intake is 
also subject to error; furthermore some day to day variabil-
ity in food intake is expected. Although estimating vitamin 
B12 content in food is not precise, it allowed us to assess an 
additional factor that could influence serum levels of this vi-
tamin. Even though the South of Brazil is a region where red 
meat is an everyday food, most of the population evaluated 
had an estimated vitamin B12 intake below the minimum 
RDI. Nutritional deficiency could have contributed to the 
low serum vitamin B12 levels in our patients.
Serum vitamin B12 levels were inversely associated with 
age. Studies evaluating the elderly population of industrial-
ized countries have shown prevalence of vitamin B12 defi-
ciency of around 20%13, implicating age as a possible risk 
factor for vitamin B12 deficiency. 
In this study, serum vitamin B12 levels were not associ-
ated with the dose of metformin, but were associated with 
treatment duration. In a case-control study that included 
155 diabetic patients with vitamin B12 deficiency, both 
emerged as independent risk factors for vitamin B12 defi-
ciency, after adjusting for potential confounding factors3. 
This discordance could be at least in part explained by the 
self-report method used in this study to determine the dose 
and duration of metformin use. Metformin has adverse ef-
fects such as diarrhea, nausea and change in taste15, which 
could cause underreported irregular use. 
This study has important limitations. Its design only 
makes it possible to evaluate associations. The absence of a 
control group makes it impossible to compare prevalence 
of vitamin B12 deficiency in a similar population not using 
metformin, which may have vitamin B12 deficiency associ-
ated with other factors, such as described in the Framingham 
study16. Nevertheless, a recent randomized controlled clini-
cal trial demonstrated an increased risk of vitamin B-12 de-
ficiency in long term treatment with metformin17. 
Figure 1 – Correlation of serum vitamin B12 levels in 
metformin-treated type 2 diabetic patients (n = 144) with 
A: daily intake of vitamin B12; B: age; C: body weight.
Variables Multivariate analysis*
B SE ` p
Estimated vitamin B12 intake 67.957 21.894 0.249 0.002
Age -3.172 1.505 -0.171 0.037
Metformin use duration -33.358 16.733 -0.161 0.048
*Model including vitamin B12 intake, age and metformin use duration, dependent variable: serum vitamin B12; adjusted R2 = 0.111
Table 2 – Factors associated with serum vitamin B12 levels in metformin-treated type 2 diabetic patients (n = 144)
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Although serum vitamin B12 level is the most used 
test to diagnose deficiency of this vitamin18,19 due to its 
low cost19, its sensitivity is not very high. It can be in the 
normal range in a significant proportion of patients with 
disabilities in which serum homocysteine or methylmalo-
nic acid levels allow the early identification of vitamin B12 
deficiency18. The large number of metformin-treated DM2 
patients at risk for vitamin B12 deficiency makes it impor-
tant to have better tests to clearly diagnose this condition, 
prior to committing these patients to lifelong treatment 
with vitamin B12. Although our study did not answer sev-
eral questions, we believe it is important to call the medical 
community’s attention to this common problem. 
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